Top Stories
Latest Coverage
A Milestone for Targeted Protein Degradation: The World’s First PROTAC Drug Approved
On May 1, 2026, the U.S. Food and Drug Administration officially approved Vepdegestrant (trade name: Veppanu) for the...
On May 1, 2026, the U.S. Food and Drug Administration officially approved Vepdegestrant (trade name: Veppanu) for the...
What Is the Difference Between Nasopharyngeal Cancer, Oropharyngeal Cancer, and Laryngeal Cancer? Understanding the Key Differences Among Three Head and Neck Cancers
Understanding the Key Differences Among Three Head and Neck Cancers
Understanding the Key Differences Among Three Head and Neck Cancers
Why Do Primary Healthcare Facilities Frequently Experience Drug Supply Shortages? Strengthening the Pharmaceutical Supply Chain for Continuous Access to Medicines
Strengthening the Pharmaceutical Supply Chain for Continuous Access to Medicines
Strengthening the Pharmaceutical Supply Chain for Continuous Access to Medicines
Why Are Trispecific Antibodies More Complex Than Bispecific Antibodies? Understanding the Design Logic Behind Trispecific Antibodies
Understanding the Design Logic Behind Trispecific Antibodies
Understanding the Design Logic Behind Trispecific Antibodies
Why Are Solid Tumors More Difficult to Treat Than Blood Cancers? Uncovering the Key Challenges Behind Cancer Therapy
Uncovering the Key Challenges Behind Cancer Therapy
Uncovering the Key Challenges Behind Cancer Therapy
Is a Trispecific Antibody Necessarily Better Than a Bispecific? An Analysis of Efficacy, Safety, and Future Applications
In recent years, bispecific antibodies (BsAbs) have become one of the most active areas of global innovative drug dev...
In recent years, bispecific antibodies (BsAbs) have become one of the most active areas of global innovative drug dev...
